FDA data Registry peer set 1 peer FDA shortage listed

Alternatives to amphotericin B

FDA shortage status is active for amphotericin B; 1 same-class SPL records are listed below for registry comparison only.

Brand: Ambisome, Fungizone

Polyene Antifungal Prescription 1 alternative found

amphotericin B class peers while FDA lists an active shortage

amphotericin B (Ambisome, Fungizone) is on an FDA shortage listing while 1 other Polyene Antifungal SPL records remain in this registry peer set (class inventory 2). Labeled indication field for amphotericin B: This medicine treats fungal infections like aspergillosis, candidiasis, and cryptococcosis.

Top FAERS reaction fields for amphotericin B total 6,391 reports across 10 reactions, set beside nystatin. Counts are exposure-weighted submissions, not per-patient risk.

About amphotericin B

Amphotericin B liposome is an antifungal medicine. It fights serious fungal infections in your body.

Used for: This medicine treats fungal infections like aspergillosis, candidiasis, and cryptococcosis. It can also treat cryptococcal meningitis in people with HIV. It may also be used for visceral leishmaniasis, but this infection can return, especially in those with weak immune systems.

1 Polyene Antifungal peers (wide set)

Compare amphotericin B vs nystatin side-by-side →

amphotericin B vs nystatin · FAERS reaction fields

FAERS top-reaction field "Condition Aggravated" shows the widest count spread between amphotericin B and nystatin in this extract (841-report gap on that field). Counts are exposure-weighted submissions, not prevalence rates.

Side Effect amphotericin B nystatin
Pyrexia 972 1,110
Condition Aggravated 841 -
Febrile Neutropenia 650 -
Acute Kidney Injury 625 957
Sepsis 613 -
Pneumonia 576 1,613
Hypokalaemia 542 -
Multiple Organ Dysfunction Syndrome 528 -

"-" means no reports for that reaction. Report counts reflect total FAERS submissions, not prevalence rates.

amphotericin B shortage vs Polyene Antifungal peer index

Shortage status

FDA shortage listing is active for amphotericin B (status: To Be Discontinued). Peer rows remain a registry index, not a switch guide.

Frequently Asked Questions

Does FDA list a shortage for amphotericin B while peers remain indexed?
Yes - amphotericin B matched an active FDA shortage listing (To Be Discontinued) while 1 other Polyene Antifungal SPL records remain in this peer index for field comparison only.

Registry note: Shortage listings and peer indexes are for registry orientation only. This information is for educational purposes only and is not a substitute for professional medical advice. Do not stop or change your medication without talking to your doctor or pharmacist.

Full amphotericin B profile →

Field note for amphotericin B: see also the generic vs brand label guide when reading Ambisome SPL strings.